STAGE IV NASOPHARYNGEAL CARCINOMA AJCC V8
Clinical trials for STAGE IV NASOPHARYNGEAL CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV NASOPHARYNGEAL CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IV NASOPHARYNGEAL CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Double immunotherapy may stall return of rare nasal cancer
Disease control Recruiting nowThis study is for people with a type of nose and throat cancer (nasopharyngeal carcinoma) that has come back or spread. After initial treatment with chemotherapy and the immunotherapy drug nivolumab, participants will receive either nivolumab alone or nivolumab plus another drug …
Matched conditions: STAGE IV NASOPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 10:21 UTC
-
Cholesterol drug boosts immunotherapy against tough head and neck cancers
Disease control Recruiting nowThis study tests whether adding a common cholesterol-lowering drug (lovastatin) to an immunotherapy (pembrolizumab) can help shrink tumors in people with head and neck cancer that has returned or spread. About 28 adults whose cancer has not responded to prior treatments will rece…
Matched conditions: STAGE IV NASOPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated May 26, 2026 10:05 UTC
-
New hope for Hard-to-Treat nasopharyngeal cancer: drug combo trial launches
Disease control Recruiting nowThis study is for people with advanced nasopharyngeal cancer that has returned or spread and no longer responds to standard treatments. It tests whether adding a targeted drug (cabozantinib) to two immunotherapy drugs (nivolumab and ipilimumab) can help shrink or stabilize the ca…
Matched conditions: STAGE IV NASOPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New combo therapy aims to shrink tumors and reduce radiation side effects in young cancer patients
Disease control Recruiting nowThis study tests whether adding the immunotherapy drug nivolumab to standard chemotherapy (gemcitabine and cisplatin) before radiation therapy is safe and effective for children and young adults (up to age 21) with newly diagnosed nasopharyngeal carcinoma. The goal is to improve …
Matched conditions: STAGE IV NASOPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
New vaccine combo aims to fight recurrent head and neck cancer
Disease control Recruiting nowThis early-phase trial tests a personalized vaccine made from a patient's own tumor cells, given alone or with an immunotherapy drug (pembrolizumab), for head and neck cancer that has returned or spread. The study aims to find the safest dose and check for side effects in 40 adul…
Matched conditions: STAGE IV NASOPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
Can a simple exercise prevent swallowing problems? new study investigates why some patients skip it.
Knowledge-focused Recruiting nowThis study looks at why people with head and neck cancer do or do not follow swallowing exercises after radiation. Researchers will use blood tests and questionnaires to see if immune system proteins or feelings about the disease affect exercise habits. The goal is to find ways t…
Matched conditions: STAGE IV NASOPHARYNGEAL CARCINOMA AJCC V8
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated May 22, 2026 13:55 UTC